IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study




To study if luteal E2 pre-treatment before GnRH antagonist protocol improves IVF/ICSI outcomes compared with standard long GnRH agonist protocol.


A prospective, randomized and controlled study.


ART center of a state public hospital


Two hundred twenty infertile women underwent IVF/ICSI treatments.


Participants received oral Estradiol Valerate 4 mg/day preceding the IVF cycle from day 21 until day 2 of next cycle before GnRH antagonist protocol (E2 pre-treatment group n = 109) or received standard long GnRH agonist protocol as control group (n = 111).

Main outcome measure(s)

Number of oocytes collected, MII oocytes, fertilization, implantation, live birth and early pregnancy rate, and hormone profiles.


E2 pre-treatment exerted a significant suppressive effect on FSH but not LH secretion compared with basal FSH and LH levels. In E2 pre-treatment group serum LH level was significantly higher during COH and serum P was also significantly higher on the day of HCG injection compared with control group. Five patients from E2 pre-treatment group had elevated LH at all time (≥10 IU/L) and also a concomitantly high P (>1 ng/mL). Two of the five women achieved pregnancy but had early pregnancy loss. Overall, IVF/ICSI outcomes such as implantation, clinical pregnancy and live birth rates were similar between E2 pre-treatment and control groups.


Luteal E2 pre-treatment before GnRH antagonist protocol significantly increases serum LH level and incidence rate of premature LH but no significant effect is observed on implantation, clinical pregnancy, live birth and early pregnancy loss rates compared with long GnRH agonist protocol. However, more studies in large numbers of cycles are needed to confirm that increased serum LH level by E2 pre-treatment during COH has no negative effect on the IVF/ICSI outcomes.


FSH Estradiol pre-treatment Controlled ovarian hyperstimulation IVF 



The authors thank Dr. De Yi Liu from the University of Melbourne, Australia, for revising the final draft of the manuscript.


  1. 1.
    Al-lnany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochcane review. Hum Reprod. 2002;17:874–85. doi: 10.1093/humrep/17.4.874.CrossRefGoogle Scholar
  2. 2.
    Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007;22:2805–13. doi: 10.1093/humrep/dem270.PubMedCrossRefGoogle Scholar
  3. 3.
    Devreker F, Pogonici E, De Maertelaer V, Revelard P, Vanden Bergh M, et al. Selection of good embryos for transfer depends on embryo cohort size: implication for the mila ovarian stimulation debate. Hum Reprod. 1999;14:3002–8. doi: 10.1093/humrep/14.12.3002.PubMedCrossRefGoogle Scholar
  4. 4.
    Opsahl MS, Blauor KL, Black SH, Lincoln SR, Thorell L, Sherins RJ. The number of embryos available for transfer predicts successful pregnancy outcome in women over 39 years with normal ovarian hormonal reserve testing. J Assist Reprod Genet. 2001;18:551–6. doi: 10.1023/A:1011906024170.PubMedCrossRefGoogle Scholar
  5. 5.
    Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation. Fertil Steril. 2003;79:316–21. doi: 10.1016/S0015-0282(02)04574-0.PubMedCrossRefGoogle Scholar
  6. 6.
    Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates folliclar growth during controlled ovarian hyperstimulation with antagonist. Hum Reprod. 2003;18:2698–703. doi: 10.1093/humrep/deg516.PubMedCrossRefGoogle Scholar
  7. 7.
    Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R. Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulations hormone and inhibin B levels and ovarian follicular status. Fertil Steril. 2003;79:585–9. doi: 10.1016/S0015-0282(02)04757-X.PubMedCrossRefGoogle Scholar
  8. 8.
    Chun SY, Eisenhauer KM, Minami S, Billig H, Perlas E, Hsueh AJ. Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone sa a major survival factor. Endocrinology. 1996;137:1447–56. doi: 10.1210/en.137.4.1447.PubMedCrossRefGoogle Scholar
  9. 9.
    Klein NA, Battaglia DE, Fujimoto VY, Davis GS, Bremner WJ, Soules MR. Reproductive aging: accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab. 1996;81:1038–45. doi: 10.1210/jc.81.3.1038.PubMedCrossRefGoogle Scholar
  10. 10.
    Hillier SG, Van den Boogaard AM, Reichert LE Jr, Van Hall EV. Intraovarian sex steroia hormme interaction and the regulation of follicular maturation: aromatization of androgens by human granulose cells in vitro. J Clin Endocrinol Metab. 1980;50(4):640–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Durnerin-Cedrin I, Bstandig B, Parneix L, et al. Effects of oral comfraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod. 2007;22:109–16. doi: 10.1093/humrep/del340.CrossRefGoogle Scholar
  12. 12.
    Laholu N, Chabbert-Buffer N, Christin-Maitre S, Le Nestour E, Roger M, Bouchard P. Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: inhibin A, Destradios, or inhibin B? Hum Reprod. 1999;14:1190–3. doi: 10.1093/humrep/14.5.1190.CrossRefGoogle Scholar
  13. 13.
    Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone in effective, safe and convenient: results of a controlled, randomize, multi-centre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1490–8. doi: 10.1093/humrep/15.7.1490.PubMedCrossRefGoogle Scholar
  14. 14.
    Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod. 2002;7:874–85.CrossRefGoogle Scholar
  15. 15.
    Huime JAF, van Loenen ACD, Schats R, McDonnell J, Hompes PGA, Schoemaker J, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LHsurges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod. 2005;20:359–67.Google Scholar
  16. 16.
    Kolibianakis EM, Zikopoulous K, Schiettecatte J, Smita J, Tournaye H, Camus M, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod. 2004;19:2490–6. doi: 10.1093/humrep/deh471.PubMedCrossRefGoogle Scholar
  17. 17.
    Rombauts L, Healy D, Norman RJ. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. On behalf of the Orgalutran Scheduling Study Group. Hum Reprod. 2006;21:95–103. doi: 10.1093/humrep/dei302.Google Scholar
  18. 18.
    Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is hv+mcnkjjassociatoal with a reduced chance of pregnancy. Fertil Steril. 2003;79:873–80. doi: 10.1016/S0015-0282(02)04920-8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Hong Ye
    • 1
  • Guo-ning Huang
    • 2
  • Ping-hong Zeng
    • 2
  • Li Pei
    • 2
  1. 1.Chongqing Reproductive and Genetic Institute, Chongqing Obstetric and Gynecology HospitalChongqingChina
  2. 2.Chongqing Reproductive and Genetic Institute, Chongqing Obstetric and Gynecology HospitalChongqingChina

Personalised recommendations